Visit main University website

University of Sydney logo

Find MND Biomarker

University of Sydney logo

Find MND Biomarker

↑

Find MND Biomarker

Welcome to FindMNDBiomarker, an integrative database that consolidates the proteomic findings in brain tissue and biofluids (CSF and blood) from patients with motor neuron disease (also known as amyotrophic lateral sclerosis). FindMNDBiomarker is designed for users to quickly assess whether their proteins of interest have been identified in other cohorts and biosamples from patients with MND/ALS.

Purpose: The goal of this search platform is to facilitate the comparison and discovery of proteins that may serve as promising and reproducible biofluid biomarkers of brain-specific changes in MND/ALS and to identify markers that should be further targeted for analyses and validation.

Using this database: Searches can be performed by entering the protein UniProt IDs, names and sample types into the relevant search term box using free text entry. For example, entering ‘NEFL’ will generate a list of all publications in which NEFL was identified to be significantly dysregulated.

A searchable and filterable table is provided with the following columns:

  • Name: Gene name corresponding to the UniProt ID
  • UniProt ID: UniProt accession number
  • Publication: Study Reference
  • Condition: e.g.ALS – Control, ALS Fast – ALS Slow
  • Sample Type: Sample type used (Abbreviations: SMNs, single motor neurons; AH, anterior horn; PH, posterior horn)
  • Regulation: Direction of change (upregulated or downregulated)
  • Cohorts: Cohort size used for each study
  • Average age at onset ± standard deviation/age range: Average age at onset of ALS cohorts with standard deviation or age range (if provided by publication)
  • Average age at collection ± standard deviation/age range: Average age at collection of ALS cohorts with standard deviation or age range (if provided by publication)
  • Average PMI (range) (hours): Average postmortem interval with range (if provided by tissue studies)

To cite this database: Further details and application of this search tool are described in our manuscript “title” that can be located with this DOI:

The FindMNDBiomarker Program: Protein Changes in Motor Neuron Disease/Amyotrophic Lateral Sclerosis Postmortem Tissue and Biofluids 

DOI: https://doi.org/10.1002/ana.27300

Contact: For help contact [email protected]
Sort by:
Total Records Found: 4574, showing 100 per page
Biomarker NameUniProt IDPublicationDisease GroupComparator GroupSample TypeRegulationCohortsAverage age at onsetAverage age at collectionAverage PMI
MCAM P43121 Trautwig et al. 2025 C9orf72 ALS Sporadic ALS CSF Down 10 C9-ALS, 35 sALS 53.9 ± 11.5, 56.4 ± 8.9 56.7 ± 10.9, 57.2 ± 8.7 N/A
MCAM P43121 Trautwig et al. 2025 C9orf72 ALS Control CSF Down 10 C9-ALS, 44 control 56.4 ± 8.9 57.2 ± 8.7 N/A
MCAM P43121 Chen et al. 2016 ALS Control CSF Down 35 ALS, 10 control N/A 52.7 ±12.13 N/A
MCAM P43121 Oeckl et al. 2020 ALS Control Spinal cord Up 8 ALS, 7 control N/A 59 (52-61) 36 (24-90)
MCA3 O43324 Andrés-Benito et al. 2020 ALS Control CSF Down 15 ALS, 15 control N/A 61 ± 10.8 N/A
MBP P02686 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
MBNL1 Q9NR56 Leoni et al. 2019 BO-ALS LO-ALS PBMCs Up 12 BO-ALS, 12 LO-ALS (39-76) (BO-ALS), (33-81) (LO-ALS) N/A N/A
MBL2 P11226 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
MB P02144 Trautwig et al. 2025 C9orf72 ALS Asymptomatic Control CSF Up 6 C9-ALS Asymptomatic, 44 control N/A 51.5 ± 18.5 N/A
MB P02144 Chia et al. 2025 ALS Control Plasma Up 231 ALS, 384 control (214 healthy control, 170 other neurological conditions) N/A 65.1 ± 10.8 N/A
MB P02144 Trautwig et al. 2025 C9orf72 ALS Control CSF Up 10 C9-ALS, 44 control 56.4 ± 8.9 57.2 ± 8.7 N/A
MATN3 O15232 Zhou et al. 2023 SO-ALS Control CSF Down 4 BO-ALS, 5 SO-ALS, 5 control 63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS) 64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS) N/A
MAT2B Q9NZL9 Leoni et al. 2019 BO-ALS LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
MAT2B Q9NZL9 Seyfried et al. 2018 ALS Control Prefrontal cortex Down 8 ALS, 8 control 60 63.5 9.1
MAT2A P31153 Trautwig et al. 2025 C9orf72 ALS Control CSF Up 10 C9-ALS, 44 control 56.4 ± 8.9 57.2 ± 8.7 N/A
MAT2A P31153 Iridoy et al. 2018 ALS Control Spinal cord (AH) Up 9 ALS, 8 control 57.6 62.8 N/A
MAT2A P31153 Leoni et al. 2019 BO-ALS LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
MAST1 Q9Y2H9 Oeckl et al. 2020 ALS Control Spinal cord Down 8 ALS, 7 control N/A 59 (52-61) 36 (24-90)
MASP2 O00187 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
MASP2 O00187 Vilardo et al. 2024 ALS (discovery cohort) Control (discovery cohort) Plasma EVs Up 61 ALS, 30 control N/A 62.88 ± 12.60 N/A
MASP1 P48740 Trautwig et al. 2025 C9orf72 ALS Sporadic ALS CSF Up 10 C9-ALS, 35 sALS 53.9 ± 11.5, 56.4 ± 8.9 56.7 ± 10.9, 57.2 ± 8.7 N/A
MASP1 P48740 Zubiri et al. 2018 ALS fast (early stage) ALS slow (early stage) Plasma Up 6 ALS-fast, 6 ALS-slow 61.3 (48-67) (ALS-fast), 58.1 (35-71) (ALS-slow) N/A N/A
MASP1 P48740 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
MASP1 P48740 Zubiri et al. 2018 Late ALS (ALS slow cohort) Early ALS (ALS slow cohort) Plasma Down 6 ALS-fast, 6 ALS-slow 61.3 (48-67) (ALS-fast), 58.1 (35-71) (ALS-slow) N/A N/A
MARS1 P56192 Guise et al. 2024 ALS Control Spinal cord (SMNs) Down 3 ALS, 3 control N/A 69.3 9.2
MARCO Q9UEW3 Hayashi et al. 2020 ALS Control CSF exosome-enriched fractions Down 3 ALS, 3 control N/A 74.3 N/A
MARCO Q9UEW3 Trautwig et al. 2025 Sporadic ALS Control CSF Up 35 sALS, 44 control 53.9 ± 11.5 56.7 ± 10.9 N/A
MARCKSL1 P49006 Trautwig et al. 2025 C9orf72 ALS Sporadic ALS CSF Up 10 C9-ALS, 35 sALS 53.9 ± 11.5, 56.4 ± 8.9 56.7 ± 10.9, 57.2 ± 8.7 N/A
MARCKSL1 P49006 Trautwig et al. 2025 C9orf72 ALS Control CSF Up 10 C9-ALS, 44 control 56.4 ± 8.9 57.2 ± 8.7 N/A
MARCKSL1 P49006 Trautwig et al. 2025 Sporadic ALS Control CSF Up 35 sALS, 44 control 53.9 ± 11.5 56.7 ± 10.9 N/A
MARCKSL1 P49006 Trautwig et al. 2025 C9orf72 ALS C9orf72 ALS Asymptomatic CSF Up 10 C9-ALS, 6 C9-ALS Asymptomatic 56.4 ± 8.9 57.2 ± 8.7, 51.5 ± 18.5 N/A
MARCKS P29966 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
MAPRE3 Q9UPY8 Iridoy et al. 2018 ALS Control Spinal cord (AH) Down 9 ALS, 8 control 57.6 62.8 N/A
MAPRE2 Q15555 Leoni et al. 2019 BO-ALS LO-ALS PBMCs Down 12 BO-ALS, 12 LO-ALS (39-76) (BO-ALS), (33-81) (LO-ALS) N/A N/A
MAPRE1 Q15691 Iridoy et al. 2018 ALS Control Spinal cord (AH) Up 9 ALS, 8 control 57.6 62.8 N/A
MAPRE1 Q15691 Leoni et al. 2019 BO-ALS LO-ALS PBMCs Up 12 BO-ALS, 12 LO-ALS (39-76) (BO-ALS), (33-81) (LO-ALS) N/A N/A
MAPK3 P27361 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
MAPK1 P28482 Seyfried et al. 2018 ALS Control Prefrontal cortex Down 8 ALS, 8 control 60 63.5 9.1
MAPK1 P28482 Trautwig et al. 2025 C9orf72 ALS Control CSF Up 10 C9-ALS, 44 control 56.4 ± 8.9 57.2 ± 8.7 N/A
MAPK1 P28482 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
MAPK1 P28482 Trautwig et al. 2025 Sporadic ALS Control CSF Up 35 sALS, 44 control 53.9 ± 11.5 56.7 ± 10.9 N/A
MAPK1 P28482 Trautwig et al. 2025 C9orf72 ALS C9orf72 ALS Asymptomatic CSF Up 10 C9-ALS, 6 C9-ALS Asymptomatic 56.4 ± 8.9 57.2 ± 8.7, 51.5 ± 18.5 N/A
MAP6D1 Q9H9H5 Iridoy et al. 2018 ALS Control Spinal cord (AH) Down 9 ALS, 8 control 57.6 62.8 N/A
MAP6 Q96JE9 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
MAP6 Q96JE9 Iridoy et al. 2018 ALS Control Spinal cord (AH) Down 9 ALS, 8 control 57.6 62.8 N/A
MAP4 P27816 Leoni et al. 2019 BO-ALS LO-ALS PBMCs Up 12 BO-ALS, 12 LO-ALS (39-76) (BO-ALS), (33-81) (LO-ALS) N/A N/A
MAP4 F8W9U4 Iridoy et al. 2018 ALS Control Spinal cord (AH) Down 9 ALS, 8 control 57.6 62.8 N/A
MAP4 P27816 Leoni et al. 2019 BO-ALS LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
MAP2K4 P45985 Oeckl et al. 2020 ALS Control Spinal cord Down 8 ALS, 7 control N/A 59 (52-61) 36 (24-90)
MAP2K2 P36507 Oeckl et al. 2020 ALS Control Spinal cord Down 8 ALS, 7 control N/A 59 (52-61) 36 (24-90)
MAP2K1 Q02750 Leoni et al. 2019 BO-ALS LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
MAP2 P11137 Iridoy et al. 2018 ALS Control Spinal cord (AH) Down 9 ALS, 8 control 57.6 62.8 N/A
MAP2 P11137 Guise et al. 2024 ALS Control Spinal cord (SMNs) Down 3 ALS, 3 control N/A 69.3 9.2
MAP2 P11137 Oeckl et al. 2020 ALS Control CSF Up 26 ALS, 16 control N/A N/A N/A
MAP1B P46821 Trautwig et al. 2025 C9orf72 ALS Sporadic ALS CSF Up 10 C9-ALS, 35 sALS 53.9 ± 11.5, 56.4 ± 8.9 56.7 ± 10.9, 57.2 ± 8.7 N/A
MAP1B P46821 Trautwig et al. 2025 C9orf72 ALS Control CSF Up 10 C9-ALS, 44 control 56.4 ± 8.9 57.2 ± 8.7 N/A
MAP1A P78559 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
MAOB P27338 Guise et al. 2024 ALS Control Spinal cord (SMNs) Up 3 ALS, 3 control N/A 69.3 9.2
MAOB P27338 Iridoy et al. 2018 ALS Control Spinal cord (AH) Up 9 ALS, 8 control 57.6 62.8 N/A
MANSC1 Q9H8J5 Trautwig et al. 2025 C9orf72 ALS Asymptomatic Control CSF Down 6 C9-ALS Asymptomatic, 44 control N/A 51.5 ± 18.5 N/A
MANSC1 Q9H8J5 Trautwig et al. 2025 C9orf72 ALS C9orf72 ALS Asymptomatic CSF Up 10 C9-ALS, 6 C9-ALS Asymptomatic 56.4 ± 8.9 57.2 ± 8.7, 51.5 ± 18.5 N/A
MAN2C1 H3BRI3 Seyfried et al. 2018 ALS Control Prefrontal cortex Down 8 ALS, 8 control 60 63.5 9.1
MAN2A2 P49641 Trautwig et al. 2025 C9orf72 ALS Sporadic ALS CSF Down 10 C9-ALS, 35 sALS 53.9 ± 11.5, 56.4 ± 8.9 56.7 ± 10.9, 57.2 ± 8.7 N/A
MAN2A2 P49641 Trautwig et al. 2025 C9orf72 ALS Control CSF Down 10 C9-ALS, 44 control 56.4 ± 8.9 57.2 ± 8.7 N/A
MAN2A2 P49641 Trautwig et al. 2025 C9orf72 ALS C9orf72 ALS Asymptomatic CSF Down 10 C9-ALS, 6 C9-ALS Asymptomatic 56.4 ± 8.9 57.2 ± 8.7, 51.5 ± 18.5 N/A
MAN1C1 Q9NR34 Trautwig et al. 2025 C9orf72 ALS Asymptomatic Control CSF Up 6 C9-ALS Asymptomatic, 44 control N/A 51.5 ± 18.5 N/A
MAN1C1 Q9NR34 Trautwig et al. 2025 C9orf72 ALS Control CSF Up 10 C9-ALS, 44 control 56.4 ± 8.9 57.2 ± 8.7 N/A
MAN1C1 Q9NR34 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
MAN1C1 Q9NR34 Trautwig et al. 2025 Sporadic ALS Control CSF Up 35 sALS, 44 control 53.9 ± 11.5 56.7 ± 10.9 N/A
MAN1A1 P33908 Trautwig et al. 2025 C9orf72 ALS Asymptomatic Control CSF Down 6 C9-ALS Asymptomatic, 44 control N/A 51.5 ± 18.5 N/A
MAMDC2 Q7Z304 Trautwig et al. 2025 C9orf72 ALS Asymptomatic Control CSF Up 6 C9-ALS Asymptomatic, 44 control N/A 51.5 ± 18.5 N/A
MAMDC2 Q7Z304 Trautwig et al. 2025 C9orf72 ALS Control CSF Up 10 C9-ALS, 44 control 56.4 ± 8.9 57.2 ± 8.7 N/A
MAL2 Q969L2 Seyfried et al. 2018 ALS Control Prefrontal cortex Up 8 ALS, 8 control 60 63.5 9.1
MAGOH P61326 Oeckl et al. 2020 ALS Control Spinal cord Up 8 ALS, 7 control N/A 59 (52-61) 36 (24-90)
MADD Q8WXG6 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
MACF1 H0Y390 Leoni et al. 2019 BO-ALS LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
M6PR P20645 Oeckl et al. 2020 ALS Control Spinal cord Up 8 ALS, 7 control N/A 59 (52-61) 36 (24-90)
LYZ P61626 Trautwig et al. 2025 C9orf72 ALS Control CSF Up 10 C9-ALS, 44 control 56.4 ± 8.9 57.2 ± 8.7 N/A
LYZ P61626 Vu et al. 2023 ALS fast ALS slow CSF Up 6 ALS-fast, 5 ALS-slow 54.3 (ALS-fast), 43.4 (ALS-slow) 55.3 (ALS-fast), 52.2 (ALS-slow)
LYZ P61626 Trautwig et al. 2025 Sporadic ALS Control CSF Up 35 sALS, 44 control 53.9 ± 11.5 56.7 ± 10.9 N/A
LYZ P61626 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
LYZ P61626 Leoni et al. 2019 BO-ALS LO-ALS PBMCs Up 12 BO-ALS, 12 LO-ALS (39-76) (BO-ALS), (33-81) (LO-ALS) N/A N/A
LYVE1 Q9Y5Y7 Trautwig et al. 2025 C9orf72 ALS Asymptomatic Control CSF Down 6 C9-ALS Asymptomatic, 44 control N/A 51.5 ± 18.5 N/A
LYVE1 Q9Y5Y7 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
LYSC P61626 Vilardo et al. 2024 ALS (validation cohort) ALS (validation cohort) Plasma EVs Up 61 ALS, 30 control N/A 62.88 ± 12.60 N/A
LYSC P61626 Oh et al. 2023 ALS Control CSF Up 20 ALS, 20 control N/A 59 N/A
LY6H O94772 Vu et al. 2023 ALS fast ALS slow CSF Up 6 ALS-fast, 5 ALS-slow 54.3 (ALS-fast), 43.4 (ALS-slow) 55.3 (ALS-fast), 52.2 (ALS-slow)
LY6E Q16553 Trautwig et al. 2025 Sporadic ALS Control CSF Up 35 sALS, 44 control 53.9 ± 11.5 56.7 ± 10.9 N/A
LXN Q9BS40 Oeckl et al. 2020 ALS Control Spinal cord Down 8 ALS, 7 control N/A 59 (52-61) 36 (24-90)
LUZP2 Q86TE4 Trautwig et al. 2025 C9orf72 ALS Asymptomatic Control CSF Down 6 C9-ALS Asymptomatic, 44 control N/A 51.5 ± 18.5 N/A
LUM P51884 Trautwig et al. 2025 C9orf72 ALS Sporadic ALS CSF Up 10 C9-ALS, 35 sALS 53.9 ± 11.5, 56.4 ± 8.9 56.7 ± 10.9, 57.2 ± 8.7 N/A
LUM P51884 Leoni et al. 2019 BO-ALS LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
LTF P02788 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
LTF E7ER44 Leoni et al. 2019 BO-ALS LO-ALS PBMCs Down 12 BO-ALS, 12 LO-ALS (39-76) (BO-ALS), (33-81) (LO-ALS) N/A N/A
LTBP4 Q8N2S1 Trautwig et al. 2025 C9orf72 ALS Asymptomatic Control CSF Up 6 C9-ALS Asymptomatic, 44 control N/A 51.5 ± 18.5 N/A
LTBP4 Q8N2S1 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
LTBP3 Q9NS15 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
LTBP2 Q14767 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
LTBP2 Q14767 Trautwig et al. 2025 C9orf72 ALS Asymptomatic Control CSF Up 6 C9-ALS Asymptomatic, 44 control N/A 51.5 ± 18.5 N/A
LTBP2 Q14767 Trautwig et al. 2025 C9orf72 ALS Control CSF Up 10 C9-ALS, 44 control 56.4 ± 8.9 57.2 ± 8.7 N/A